Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anand Mattai is active.

Publication


Featured researches published by Anand Mattai.


Brain Stimulation | 2011

Tolerability of transcranial direct current stimulation in childhood-onset schizophrenia

Anand Mattai; Rachel Miller; Brian Weisinger; Deanna Greenstein; Jennifer L. Bakalar; Julia W. Tossell; Christopher N. David; Eric M. Wassermann; Judith L. Rapoport; Nitin Gogtay

BACKGROUND In recent years, transcranial direct current stimulation (tDCS) has been used to study and treat many neuropsychiatric conditions. However, information regarding its tolerability in the pediatric population is lacking. OBJECTIVE This study aims to investigate the tolerability aspects of tDCS in the childhood-onset schizophrenia (COS) population. METHODS Twelve participants with COS completed this inpatient study. Participants were assigned to one of two groups: bilateral anodal dorsolateral prefrontal cortex (DLPFC) stimulation (n = 8) or bilateral cathodal superior temporal gyrus (STG) stimulation (n = 5). Patients received either 2 mA of active treatment or sham treatment (with possibility of open active treatment) for 20 minutes, for a total of 10 sessions (2 weeks). RESULTS tDCS was well tolerated in the COS population with no serious adverse events occurring during the study. CONCLUSIONS This is the first study to demonstrate that a 20-minute duration of 2 mA of bilateral anodal and bilateral cathodal DC polarization to the DLPFC and STG was well tolerated in a pediatric population.


Journal of the American Academy of Child and Adolescent Psychiatry | 2011

Childhood Onset Schizophrenia: High Rate of Visual Hallucinations

Christopher N. David; Deanna Greenstein; Liv Clasen; Pete Gochman; Rachel Miller; Julia W. Tossell; Anand Mattai; Nitin Gogtay; Judith L. Rapoport

OBJECTIVE To document high rates and clinical correlates of nonauditory hallucinations in childhood onset schizophrenia (COS). METHOD Within a sample of 117 pediatric patients (mean age 13.6 years), diagnosed with COS, the presence of auditory, visual, somatic/tactile, and olfactory hallucinations was examined using the Scale for the Assessment of Positive Symptoms (SAPS). We also compared hallucination modality membership (presence/absence) groups on gender, socioeconomic status, ethnicity, age of onset (of psychosis), Full Scale IQ, Verbal IQ, and clinical severity (Childrens Global Assessment Scale [CGAS) and Scale for the Assessment of Negative Symptoms [SANS]). RESULTS A total of 111 COS patients (94.9%) had auditory and 94 patients (80.3%) had visual hallucinations. Somatic/tactile (60.7%) and olfactory (29.9%) hallucinations occurred almost exclusively in patients who also had visual hallucinations. Children who had visual hallucinations had lower IQ, earlier age of onset, and more severe illness relative to children who did not have visual hallucinations. CONCLUSIONS In this study, we observed that patients with COS have high rates of hallucinations across all modalities. An increased rate of visual hallucinations is associated with greater clinical impairment and greater compromise in overall brain functioning. Somatic and olfactory hallucinations reflect an additive rather than alternative symptom pattern.


Schizophrenia Research | 2010

Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia

Anand Mattai; Alex Chavez; Deanna Greenstein; Liv Clasen; Jennifer L. Bakalar; Reva Stidd; Judith L. Rapoport; Nitin Gogtay

BACKGROUND Little is known about the effects of antipsychotic medications on gray matter (GM) in schizophrenia. Although clozapine remains the most effective antipsychotic medication in treatment-refractory cases, it is unknown whether it has a differential effect on GM development. METHODS In an exploratory analysis, we used automated cortical thickness measurements and prospectively scanned childhood-onset schizophrenia (COS) patients who were maintained on one medication. Two atypical antipsychotic medications, clozapine (n=12, 37 scans) and olanzapine (n=12, 33 scans) were compared with respect to effects on cortical development, in contrast to GM trajectories of matched controls. RESULTS There were no significant differences in the trajectories of cortical thickness between the two treatment groups with the exception of a small circumscribed area in the right prefrontal cortex, where the olanzapine group showed thicker cortex. As expected, both groups showed thinner GM compared to matched controls. CONCLUSIONS Although these analyses do not rule out effects of antipsychotic medications on GM development in schizophrenia, they show no differential effect between clozapine and olanzapine on GM trajectory.


Psychiatric Genetics | 2012

Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia.

Yohan Lee; Anand Mattai; Robert Long; Judith L. Rapoport; Nitin Gogtay; Anjene Addington

Childhood-onset schizophrenia (COS) is a rare severe form of schizophrenia that may have greater salient genetic risk. Despite evidence for high heritability, conclusive genetic causes of schizophrenia remain elusive. Recent genomic technologies in concert with large case–control cohorts have led to several associations of highly penetrant rare copy number variants (CNVs) and schizophrenia. We previously reported two patients with COS who carried a microduplication disrupting the PXDN and MYT1L genes at 2p25.3. This rate of duplications within our COS population (N=92) is significantly higher than that in 2026 healthy controls (P=0.002). As a replication, we report a meta-analysis of four recently published studies that together provide strong evidence for an association between variably sized microduplications involving the MYT1L gene and schizophrenia. None have reported this separately. Altogether, among 5325 patients and 9279 controls, 10 microduplications were observed: nine in patients and one in a control (odds ratio=15.7, P=0.001). Further, the 2% rate observed in our COS patients is also significantly higher than the rate in adult-onset cases (0.14%, odds ratio=16.6, P=0.01). This report adds to the growing body of literature implicating rare CNVs as risk factors for schizophrenia and shows that some risk CNVs are more common among extreme early-onset cases.


Schizophrenia Research | 2009

General absence of abnormal cortical asymmetry in childhood-onset schizophrenia: A longitudinal study

Jennifer L. Bakalar; Deanna Greenstein; Liv Clasen; Julia W. Tossell; Rachel Miller; Alan C. Evans; Anand Mattai; Judith L. Rapoport; Nitin Gogtay

BACKGROUND Childhood-onset schizophrenia (COS) is a rare, severe form of the adult-onset illness, with more salient neurobiological causes. Previous cross-sectional structural neuroimaging research has suggested that normal cortical asymmetry patterns [(R-L)/(R+L)] may be altered in adult schizophrenia, although these findings were not well replicated. Recent studies show dynamic changes in brain asymmetry during childhood and adolescence. We hypothesized that COS patients would show a lack of normal development of asymmetry and decreased overall asymmetry. METHODS Prospective structural magnetic resonance scans were obtained at baseline and at two-year follow-up visits in 49 right-handed COS patients (mean baseline age: 14.72+/-2.63, 117 scans) and 50 age and sex-matched, right-handed healthy controls (mean baseline age: 15.15+/-3.37, 125 scans). Cortical thickness was calculated at 40,962 homologous points across each cerebral hemisphere using a fully automated, validated method. Differences in developmental asymmetry patterns across the cortical surface were analyzed using a linear mixed effects regression model. RESULTS No significant asymmetry differences were found either for cross-sectional comparisons of COS and healthy controls across the lateral and medial cortical surfaces or with respect to timing of developmental changes in asymmetry. CONCLUSIONS The present findings do not support asymmetry differences for this severe, early form of schizophrenia.


Human Psychopharmacology-clinical and Experimental | 2009

Adjunctive Use of Lithium Carbonate for the Management of Neutropenia in Clozapine-Treated Children

Anand Mattai; Lawrence K. Fung; Jennifer L. Bakalar; Gerald P. Overman; Julia W. Tossell; Rachel Miller; Judith L. Rapoport; Nitin Gogtay

Clozapine, a dibenzodiazepine antipsychotic, is the most effective medication for treatment‐resistant schizophrenia. However, its use has been limited by the high risk of neutropenia. In children, the rate of neutropenia is higher when compared to adults. We decided to explore the use of lithium to manage neutropenia in childhood‐onset schizophrenia (COS) through a systematic audit of COS cases.


Schizophrenia Bulletin | 2013

Lack of Gender Influence on Cortical and Subcortical Gray Matter Development in Childhood-Onset Schizophrenia

Brian Weisinger; Deanna Greenstein; Anand Mattai; Liv Clasen; Francois Lalonde; Sara Feldman; Rachel Miller; Julia W. Tossell; Nora S. Vyas; Reva Stidd; Christopher N. David; Nitin Gogtay

BACKGROUND Progressive cortical gray matter (GM) abnormalities are an established feature of schizophrenia and are more pronounced in rare, severe, and treatment refractory childhood-onset schizophrenia (COS) cases. The effect of sex on brain development in schizophrenia is poorly understood and studies to date have produced inconsistent results. METHODS Using the largest to date longitudinal sample of COS cases (n = 104, scans = 249, Male/Female [M/F] = 57/47), we compared COS sex differences with sex differences in a sample of matched typically developing children (n = 104, scans = 244, M/F = 57/47), to determine whether or not sex had differential effects on cortical and subcortical brain development in COS. RESULTS Our results showed no significant differential sex effects in COS for either GM cortical thickness or subcortical volume development (sex × diagnosis × age interaction; false discovery rate q = 0.05). CONCLUSION Sex appears to play a similar role in cortical and subcortical GM development in COS as it does in normally developing children.


Psychiatry Research-neuroimaging | 2013

Quantitative morphology of the corpus callosum in obsessive–compulsive disorder

Katherine C. Lopez; Francois Lalonde; Anand Mattai; Benjamin Wade; Liv Clasen; Judith L. Rapoport; Jay N. Giedd

Neuroimaging studies have implicated the corpus callosum (CC) in the pathophysiology of obsessive-compulsive disorder (OCD). Putative dysfunctions in prefrontal cortical regions suggest anomalies in anterior segments of the CC. However, recent studies have also implicated the middle and posterior CC. The present study soughts to examine the CC using parcellation scheme informed by diffusion tensor imaging. Anatomic brain magnetic resonance scans were obtained from 21 OCD subjects (mean age=26.9 ± 9.93) and 42 healthy age- and sex-matched controls (mean age=26.6 ± 9.46) between the ages of 14 and 49. Area and volume measures of five subregions of the CC were obtained via manual tracings. A multivariate analysis of variance (after correcting for multiple comparisons) identified smaller area and volume in the mid-anterior region of the CC in OCD patients relative to controls. These findings implicate medio-frontal regions of the cortex in the pathophysiology of OCD.


Journal of the American Academy of Child and Adolescent Psychiatry | 2005

Hormonal Correlates of Clozapine-Induced Weight Gain in Psychotic Children: An Exploratory Study

Alexandra Sporn; Aaron J. Bobb; Nitin Gogtay; Hanna E. Stevens; Deanna Greenstein; Liv Clasen; Julia W. Tossell; Thomas Nugent; Peter Gochman; Wendy Sharp; Anand Mattai; Marge Lenane; Jack A. Yanovski; Judith L. Rapoport


Journal of the American Academy of Child and Adolescent Psychiatry | 2011

Normalization of Cortical Gray Matter Deficits in Nonpsychotic Siblings of Patients With Childhood-Onset Schizophrenia

Anand Mattai; Brian Weisinger; Deanna Greenstein; Reva Stidd; Liv Clasen; Rachel Miller; Julia W. Tossell; Judith L. Rapoport; Nitin Gogtay

Collaboration


Dive into the Anand Mattai's collaboration.

Top Co-Authors

Avatar

Nitin Gogtay

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Judith L. Rapoport

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Liv Clasen

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Deanna Greenstein

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Julia W. Tossell

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Rachel Miller

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Brian Weisinger

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Christopher N. David

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Reva Stidd

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Francois Lalonde

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge